4553 Stock Overview Researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Towa Pharmaceutical Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Towa Pharmaceutical Historical stock prices Current Share Price JP¥3,070.00 52 Week High JP¥3,240.00 52 Week Low JP¥2,320.00 Beta -0.053 1 Month Change 8.87% 3 Month Change 0.66% 1 Year Change 30.25% 3 Year Change 12.21% 5 Year Change 7.87% Change since IPO 33.62%
Recent News & Updates
Towa Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 13, 2025 Dec 07
First half dividend of JP¥30.00 announced Dec 03
Consensus EPS estimates increase by 25% Nov 20
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 15
Is Towa Pharmaceutical (TSE:4553) A Risky Investment? Nov 13
Upcoming dividend of JP¥30.00 per share Sep 20 See more updates
Towa Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 13, 2025 Dec 07
First half dividend of JP¥30.00 announced Dec 03
Consensus EPS estimates increase by 25% Nov 20
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 15
Is Towa Pharmaceutical (TSE:4553) A Risky Investment? Nov 13
Upcoming dividend of JP¥30.00 per share Sep 20
Towa Pharmaceutical (TSE:4553) Will Pay A Dividend Of ¥30.00 Sep 05
Towa Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 12, 2024 Sep 05
Consensus EPS estimates increase by 11% Aug 23
Towa Pharmaceutical (TSE:4553) Is Due To Pay A Dividend Of ¥30.00 Aug 15
First quarter 2025 earnings: EPS and revenues exceed analyst expectations Aug 09
Investor sentiment deteriorates as stock falls 16% Aug 05
Fewer Investors Than Expected Jumping On Towa Pharmaceutical Co., Ltd. (TSE:4553) Aug 03
Final dividend of JP¥30.00 announced Jul 11
Towa Pharmaceutical's (TSE:4553) Earnings Are Weaker Than They Seem Jul 03
New minor risk - Earnings quality Jul 03
Less than half of directors are independent Jun 29
Towa Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 08, 2024 Jun 26 Towa Pharmaceutical Co., Ltd. Files New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for the Rivastigmine Twice Weekly Transdermal Patch for Treating Mild to Moderate Dementia Associated with Alzheimer's Disease Jun 08
Towa Pharmaceutical Co., Ltd. Announces Board and Committee Resignations May 23
Price target decreased by 8.1% to JP¥3,393 May 23
Full year 2024 earnings: EPS exceeds analyst expectations May 18
Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024 May 16
Upcoming dividend of JP¥30.00 per share Mar 21
Price target increased by 7.6% to JP¥3,690 Mar 09
Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024 Mar 02
Consensus EPS estimates increase by 38% Feb 21
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Feb 14
Investor sentiment improves as stock rises 20% Feb 14
Towa Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 13, 2024 Dec 28
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 15
Price target increased by 12% to JP¥3,150 Oct 28
Towa Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 13, 2023 Oct 05
Upcoming dividend of JP¥30.00 per share at 2.1% yield Sep 21
Price target increased by 18% to JP¥2,228 Aug 22
Consensus EPS estimates increase by 14% Aug 17
Investor sentiment improves as stock rises 18% Aug 17
New minor risk - Share price stability Aug 15
First quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 12
Less than half of directors are independent Jul 15
Towa Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 10, 2023 Jun 17
New major risk - Dividend sustainability Jun 12
Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023 May 17
Full year 2023 earnings: EPS and revenues miss analyst expectations May 17
Upcoming dividend of JP¥30.00 per share at 3.2% yield Mar 23
Price target decreased by 11% to JP¥2,120 Mar 18
Price target decreased by 13% to JP¥2,370 Feb 16
Third quarter 2023 earnings released: JP¥14.38 loss per share (vs JP¥117 profit in 3Q 2022) Feb 14
Towa Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 13, 2023 Dec 28
Consensus EPS estimates fall by 13% Nov 29
Consensus EPS estimates fall by 19% Nov 21
Less than half of directors are independent Nov 16
Upcoming dividend of JP¥30.00 per share Sep 22
Towa Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022 Sep 02
First quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 12
Price target decreased to JP¥2,800 Jul 09
Towa Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 10, 2022 Jun 29
Price target decreased to JP¥3,167 Jun 07
Full year 2022 earnings: EPS and revenues miss analyst expectations May 16 Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2022 May 15
Less than half of directors are independent Apr 27
Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022 Apr 04
Upcoming dividend of JP¥33.00 per share Mar 23
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 20
Second quarter 2022 earnings released: EPS JP¥79.88 (vs JP¥59.25 in 2Q 2021) Nov 16
Investor sentiment deteriorated over the past week Oct 28
Price target increased to JP¥3,364 Sep 30
Upcoming dividend of JP¥27.00 per share Sep 22
Price target increased to JP¥3,084 Sep 02
First quarter 2022 earnings released: EPS JP¥108 (vs JP¥67.77 in 1Q 2021) Aug 18
Full year 2021 earnings released: EPS JP¥284 (vs JP¥295 in FY 2020) May 17
Upcoming dividend of JP¥22.00 per share Mar 23
Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 14, 2021 Mar 07
Luye Pharma Switzerland AG and Towa Pharmaceutical Co., Ltd. Enters Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan Feb 18
New 90-day high: JP¥2,237 Feb 15
Third quarter 2021 earnings released: EPS JP¥64.94 (vs JP¥79.32 in 3Q 2020) Feb 14
Revenue and earnings beat expectations Feb 14
New 90-day high: JP¥2,093 Jan 29
New 90-day low: JP¥1,862 Dec 07
Towa Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 12, 2021 Nov 29
Towa Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 13, 2020 Aug 30 Shareholder Returns 4553 JP Pharmaceuticals JP Market 7D 10.6% -0.1% -1.5% 1Y 30.3% 10.6% 13.7%
See full shareholder returns
Return vs Market: 4553 exceeded the JP Market which returned 13.7% over the past year.
Price Volatility Is 4553's price volatile compared to industry and market? 4553 volatility 4553 Average Weekly Movement 3.8% Pharmaceuticals Industry Average Movement 3.8% Market Average Movement 3.6% 10% most volatile stocks in JP Market 7.3% 10% least volatile stocks in JP Market 1.9%
Stable Share Price: 4553 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4553's weekly volatility (4%) has been stable over the past year.
About the Company Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It also offers IT service related to healthcare; and disease risk testing services.
Show more Towa Pharmaceutical Co., Ltd. Fundamentals Summary How do Towa Pharmaceutical's earnings and revenue compare to its market cap? 4553 fundamental statistics Market cap JP¥151.13b Earnings (TTM ) JP¥15.78b Revenue (TTM ) JP¥243.94b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4553 income statement (TTM ) Revenue JP¥243.94b Cost of Revenue JP¥155.89b Gross Profit JP¥88.06b Other Expenses JP¥72.28b Earnings JP¥15.78b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
Earnings per share (EPS) 320.45 Gross Margin 36.10% Net Profit Margin 6.47% Debt/Equity Ratio 134.1%
How did 4553 perform over the long term?
See historical performance and comparison Dividends
2.0% Current Dividend Yield When do you need to buy 4553 by to receive an upcoming dividend? Towa Pharmaceutical dividend dates Ex Dividend Date Mar 28 2025 Dividend Pay Date Jun 26 2025 Days until Ex dividend 94 days Days until Dividend pay date 184 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 17:52 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Towa Pharmaceutical Co., Ltd. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Atsushi Seki Barclays Ritsuo Watanabe BofA Global Research Hidemaru Yamaguchi Citigroup Inc
Show 12 more analysts 
